OE19 Cells

OE19 is a human oesophageal adenocarcinoma cell line derived from the primary tumor of a patient with Barrett’s oesophagus-associated adenocarcinoma. This cell line is widely utilized in research focused on oesophageal cancers, particularly for investigating tumorigenesis in the context of Barrett’s oesophagus progression. OE19 serves as a model to study the molecular mechanisms underlying adenocarcinoma development, therapeutic responses, and resistance mechanisms in upper gastrointestinal malignancies.

OE19 cells exhibit an epithelial morphology and adhere under standard culture conditions. They are characterized by genomic alterations and molecular features typical of oesophageal adenocarcinoma, including overexpression of HER2/neu (ERBB2), a hallmark of aggressive tumor behavior and a clinically significant target for therapy. This makes OE19 particularly relevant for testing HER2-targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors. Additionally, OE19 cells are used to explore signaling pathways critical to cancer progression, including MAPK/ERK and PI3K/AKT pathways, as well as mechanisms of immune evasion and interaction with the tumor microenvironment.

In preclinical studies, OE19 is valuable for evaluating chemotherapeutic agents, targeted therapies, and novel combinations aimed at overcoming drug resistance. The cell line is also employed in xenograft models to assess tumor growth and therapeutic efficacy in vivo. Its molecular profile and relevance to Barrett’s oesophagus-related adenocarcinoma make OE19 a significant resource for advancing the understanding and treatment of this challenging malignancy.